Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis

Linezolid, a component of rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) treatment, is associated with treatment-limiting toxicities, including anemia. Patient-level and linezolid pharmacokinetic risk factors for anemia have not been well described in children treated for RR/MDR-T...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical infectious diseases Ročník 79; číslo 6; s. 1495
Hlavní autoři:	Brooks, Jordan T, Solans, Belén P, Béranger, Agathe, Schaaf, H Simon, van der Laan, Louvina, Sharma, Sangeeta, Furin, Jennifer, Draper, Heather R, Hesseling, Anneke C, Garcia-Prats, Anthony J, Savic, Radojka M
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 17.12.2024
Témata:	Adolescent Anemia Antitubercular Agents - adverse effects Antitubercular Agents - pharmacokinetics Antitubercular Agents - therapeutic use Child Child, Preschool Female Humans India - epidemiology Linezolid - administration & dosage Linezolid - adverse effects Linezolid - pharmacokinetics Linezolid - therapeutic use Male Prospective Studies Rifampin - pharmacokinetics Rifampin - therapeutic use Risk Factors South Africa Tuberculosis, Multidrug-Resistant - drug therapy South Africa India pharmacokinetics linezolid dosing children anemia
ISSN:	1537-6591, 1537-6591
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!